WorksheetsID: HIV
Total questions: 28
Worksheet time: 19mins
Initial ART drugs One pill , Once daily?
Biktarvy
Triumeq
Dovato
Tivcay+Truvada
Tivicay+ Descovy
Initial ART Two pills , once daily
Biktarvy
Dovato
Triumeq
Tivicay + Truvada
Tivicay + descovy
biktarvy generic components
bictegravir
emtricitabine
TAF
TDF
Trimueq Generic components
Dolutegravir
Abacavir
Lamivudine
TDF
Dovato generic components
Dolutegravir
Lamivudine
TDF
Abacavir
Tivicay+ Truvada generic
Dolutgravir
TDF
TAF
emtricitabine
Tivicay +Descovy
Dolutegravir
TAF
TDF
Emtricitabine
which drug requires testing for HLAB*5701 due to abacavir
Biktarvy
Trimueq
Dovato
Tivicay+Truvada
Tivicay +descovy
MOA: Competitively inhibit the reverse transcriptase enzyme, preventing the conversion of HIV RNA to HIV DNA
NRTI
INSTI
NNRTI
PI
NRTI Drugs ?
Z<3 LATTE
Abacavir
Emtricitibine
Lamivudine
TDF
TAF
Zidovudine
Bictegravir
Cabotegravir
Dolutegravir
Eltegravir
Raltegravir
Efavirenz
Rilpivirine
Atazanavir
Darunavir
Ritonavir
Cobicistat
MOA: Block the integrase enzyme, preventing the HIV DNA from inserting into host cell DNA
NRTI
NNRTI
INSTI
PI
INSTI Drugs
BCRED
Efavirenz
Rilpivirine
Bictegravir
Cabotegravir
Dolutegravir
Eltegravir
Raltegravir
Abacavir
Emtricitibine
Lamivudine
TDF
TAF
Zidovudi
Atazanavir
Darunavir
Ritonavir
Cobicistat
MOA: Non-competitively inhibit the reverse transcriptase enzyme, preventing the conversion of HIV RNA to HIV DNA
INSTI
PI
NRTI
NNRTI
NNRTI Drugs
Atazanavir
Darunavir
Ritonavir
Cobicistat
Efavirenz
Rilpivirine
ictegravir
Cabotegravir
Dolutegravir
Eltegravir
Raltegravir
Abacavir
Emtricitibine
Lamivudine
TDF
TAF
Zidovudine
MOA: Inhibit the HIV protease enzyme, preventing the long viral protein chains from being broken down into smaller chains needed to produce mature virus during the budding and maturation of HIV life cycle.
INST
NRTI
PI
NNRTI
Protease Inhibitor drugs
" Navir+stat"
Abacavir
Emtricitibine
Lamivudine
TDF
TAF
Zidovudin
Bictegravir
Cabotegravir
Dolutegravir
Eltegravir
Raltegravir
Efavirenz
Rilpivirine
Atazanavir
Darunavir
Ritonavir
Cobicistat
MOA: They are inhibitors of CYP3A4. They inhibit ART metabolism (e.g, PIs, elvitegravir), which increases (boosts) the ART level of therapeutic effects, the ART level and therapeutic effects. They are NOT interchangeable, do not use both together
Boosted PI drug?
Ritonavir
Cobicistat
Darunavir
Ataznavir
what drugs contain Cobicistat (Tybost)
Genvoya
Striblid
Symtuza
Evotaz
Cabenuva
MOA: Blocks HIV from binding and subsequently entering the CD4 cell in virus strain that use the CCR5 co-receptor
NNRTI
INSTI
PI
CCR5
CCR5 Drug and pearls
Maraviroc (Selzentry)
Fostemsavir (Rukobia)
Must have tropism assay results before starting (determines if the HIV strain can only bind to CCR5 co-receptor)
Hepatotoxicity
Hypersensitivity reaction
Infusion related reactions (observe for 1 hour after first infusion), diarrhea, dizziness, nausea, rash
ALL NRTI drugs
lactic acidosis w/ hepatomegaly
HBV and HIV co-Infection
Rash/severe rash
Hepatotoxicity
which med can cause darkened spots on the palms of hands and on the soles of the feet
Dovato
Tivicay+truvada
Tivivay+descovy
Biktarvy
which drugs need to be seperated from cations and antacids
Biktarvy
Dovato
Trimueq
Tivacay+truvada
Tivicay+descovy
Match Drug class with SE/warning
NRTI
rash/hepatoxic
PI can cause
high BG, TG
INSTI
myopathy
NNRTI
Rash/severe rash
Hepatotoxicity
PEP
After HIV exposure
start within 72 hours and take for 28 days.
start within 42 hours and take for 28 days.
Truvada + Dolutegravir (Tivicay) or Raltogravir (Isentress)
Truvada or Descovy
Pre-exposure prophylaxis (PrEP) is a strategy of prescribing ART to prevent HIV infection in patients who engage in high-risk activities
PrEP Treatment Options
Truvada or Descovy PO QD, no more than a 90 day supply provided at a time
Follow up: every 3 months
Cabotegravir (Apretude) IM monthly for 2 doses then every 2 months
Follow up: a month after first dose, then every 2 months
Truvada + Dolutegravir (Tivicay) or Raltogravir (Isentress)
Biktarvy
PI
Navirs
Metabolic abnormalities: hyperglycemia/insulin resistance, dyslipidemia (increase LDL, increase TGs), increase body fat and lipodystrophy
Increase CVD risk
DDI:
Antacids and H2RAs: separate
Darunavir, Fosamprenavir, Tipranavir
Caution with sulfa allergy
Hypersensitivity reactions (including SJS/TEN), orthostatic hypotension in patients with renal impairment
Must maintain effective HBV treatment in patients co-infected with HBV
PI DIs
Alpha 1 blockers (alfuzosin, silodosin, tamsulosin)
Azole antifungals
Amiodarone, dronedarone
Anticoagulants/antiplatelets: apixaban, rivaroxaban, ticagrelor
Lovastatin and Simvastatin
PDE-5 inhibitors (sildenafil, tadalafil)
NSAIDS
SSRI
5Gs
